Other formats:
BibTeX
LaTeX
RIS
@article{1788739,
author = {Novák, Jan and Macháčková, Táňa and Krejčí, Jan and Dobrovolná, Julie and Slabý, Ondřej},
article_location = {Lake Haven},
article_number = {12},
doi = {http://dx.doi.org/10.7150/thno.56327},
keywords = {microRNA; biomarker; cardiac allograft transplantation; acute cellular rejection; vasculopathy},
language = {eng},
issn = {1838-7640},
journal = {Theranostics},
title = {MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice},
url = {https://www.thno.org/v11p6058.htm},
volume = {11},
year = {2021}
}
TY - JOUR
ID - 1788739
AU - Novák, Jan - Macháčková, Táňa - Krejčí, Jan - Dobrovolná, Julie - Slabý, Ondřej
PY - 2021
TI - MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice
JF - Theranostics
VL - 11
IS - 12
SP - 6058-6073
EP - 6058-6073
PB - Ivyspring International Publisher
SN - 18387640
KW - microRNA
KW - biomarker
KW - cardiac allograft transplantation
KW - acute cellular rejection
KW - vasculopathy
UR - https://www.thno.org/v11p6058.htm
N2 - Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.
ER -
NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ and Ondřej SLABÝ. MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice. \textit{Theranostics}. Lake Haven: Ivyspring International Publisher, 2021, vol.~11, No~12, p.~6058-6073. ISSN~1838-7640. Available from: https://dx.doi.org/10.7150/thno.56327.
|
